Diabetes Care, Vol 21, Issue 12 2056-2061, Copyright © 1998 by American Diabetes Association

ARTICLES

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes

DE Kelley, P Bidot, Z Freedman, B Haag, D Podlecki, M Rendell, D Schimel, S Weiss, T Taylor, A Krol and J Magner
University of Pittsburgh School of Medicine, Division of Endocrinology, PA 15261, USA.

OBJECTIVE: To demonstrate the efficacy, tolerability, and safety of acarbose compared with placebo in patients with type 2 diabetes inadequately controlled with diet and insulin. RESEARCH DESIGN AND METHODS: A multicenter randomized double-blind placebo-controlled parallel-group comparison study was conducted. The trial was 26 weeks with a 2-week screening period and a 24-week period of treatment with acarbose or placebo, with forced titration from 25 mg t.i.d. to 50 mg t.i.d. after 4 weeks, and titration of 50 mg t.i.d. to 100 mg t.i.d. after 12 weeks based on glucose control. The dosage of insulin was to remain stable. The primary efficacy variable was mean change from baseline in HbA1c, and secondary efficacy variables included mean changes in fasting and postprandial plasma glucose and triglyceride levels. RESULTS: The addition of acarbose to the treatment of patients receiving background insulin and diet therapy resulted in a statistically significant reduction in mean HbA1c of 0.69% compared with placebo. There were statistically significant reductions in postprandial plasma glucose and glucose area under the curve, and in postprandial serum triglyceride levels in the acarbose-treated patients. Gastrointestinal side effects were more frequently reported in the acarbose-treated patients. There were no significant differences in hypoglycemic events or liver transaminase elevations between groups. CONCLUSIONS: This study demonstrated that the addition of acarbose to patients with type 2 diabetes who are inadequately controlled with insulin and diet is safe and generally well tolerated and that it significantly lowers HbA1c and postprandial glucose levels.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S.-H. Hsiao, L.-H. Liao, P.-N. Cheng, and T.-J. Wu Hepatotoxicity Associated with Acarbose Therapy Ann. Pharmacother., January 1, 2006; 40(1): 151 - 154. [Abstract] [Full Text] [PDF]

				J. Burke Review: Combination treatment with insulin and oral agents in type 2 diabetes mellitus The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 71 - 76. [Abstract] [PDF]

				J. Davidson Should Postprandial Glucose Be Measured and Treated to a Particular Target? Yes. Diabetes Care, June 1, 2003; 26(6): 1919 - 1921. [Full Text] [PDF]

				D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]

				R. Gadsby Using insulin earlier in the treatment of type 2 diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2003; 3(2): 119 - 122. [Abstract] [PDF]

				P. Phillips, J. Karrasch, R. Scott, D. Wilson, and R. Moses Acarbose Improves Glycemic Control in Overweight Type 2 Diabetic Patients Insufficiently Treated With Metformin Diabetes Care, February 1, 2003; 26(2): 269 - 273. [Abstract] [Full Text] [PDF]

				H. Yki-Järvinen Combination Therapies With Insulin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 758 - 767. [Full Text]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]